| scholarly article | Q13442814 |
| P50 | author | Falk Nimmerjahn | Q1394084 |
| Gero Brockhoff | Q50638431 | ||
| P2093 | author name string | Florian Weber | |
| Alexander Kroemer | |||
| Olaf Ortmann | |||
| Gero Brockhoff | |||
| Anja K Wege | |||
| P2860 | cites work | Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 |
| Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action | Q40016459 | ||
| Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer | Q40073275 | ||
| Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance | Q40109415 | ||
| Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. | Q40355339 | ||
| Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma | Q40562102 | ||
| Effect of FCGR2A and FCGR3A variants on CLL outcome | Q42939043 | ||
| Phenotypic and functional separation of memory and effector human CD8+ T cells | Q42951823 | ||
| Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial | Q43466172 | ||
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | Q43951696 | ||
| High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. | Q46117208 | ||
| Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. | Q47766707 | ||
| CD27 defines phenotypically and functionally different human NK cell subsets | Q49167535 | ||
| Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 | Q62604205 | ||
| Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 | ||
| ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy | Q27851876 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer | Q33418729 | ||
| Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients | Q33644305 | ||
| Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo | Q33760403 | ||
| Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity | Q34016504 | ||
| Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype | Q34434169 | ||
| Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? | Q35906275 | ||
| IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ. | Q35979037 | ||
| Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity | Q36014411 | ||
| Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. | Q36139709 | ||
| Resistance to Trastuzumab in Breast Cancer. | Q36318226 | ||
| Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor | Q36363861 | ||
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 | ||
| Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy | Q36646476 | ||
| Correlation between NK function and response to trastuzumab in metastatic breast cancer patients | Q36702442 | ||
| IL-15 trans-presentation promotes human NK cell development and differentiation in vivo | Q37061837 | ||
| Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients | Q37292031 | ||
| Safety and immunologic effects of IL-15 administration in nonhuman primates | Q37352474 | ||
| A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease | Q37371654 | ||
| Regulatory T cells and breast cancer: implications for immunopathogenesis | Q37787092 | ||
| Activity and resistance of trastuzumab according to different clinical settings. | Q37897395 | ||
| The immune system and response to HER2-targeted treatment in breast cancer | Q38183569 | ||
| Natural and therapy-induced immunosurveillance in breast cancer | Q38601420 | ||
| CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. | Q38875316 | ||
| Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages | Q38896842 | ||
| Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide | Q39456593 | ||
| Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors | Q39501392 | ||
| Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy | Q39547654 | ||
| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody | Q39705098 | ||
| Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. | Q39901596 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 2731-2744 | |
| P577 | publication date | 2016-11-07 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). | |
| P478 | volume | 8 |
| Q47277628 | Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins |
| Q40049630 | Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
Search more.